ADMA Biologics Faces Class Action Over Alleged Revenue Misconduct
Investors who lost more than $100,000 in ADMA Biologics stock have until August 10, 2026, to file as lead plaintiffs in a securities class action lawsuit. The litigation, pending in the U.S. District Court for the District of New Jersey, centers on allegations of undisclosed transactions and improper accounting practices.
The lawsuit, Mazzarino v. ADMA Biologics, Inc., covers individuals who acquired the company’s securities between August 9, 2024, and March 25, 2026. Plaintiffs allege that ADMA and its executives violated federal securities laws by withholding material information regarding the firm's financial health. Specifically, the complaint claims the company engaged in undisclosed related-party transactions and utilized channel stuffing to artificially inflate revenue figures. Furthermore, the suit asserts that ADMA lacked sufficient internal controls, rendering public statements about its business operations misleading to shareholders. Those seeking to discuss potential legal options are directed to the law firm Kahn Swick & Foti, LLC, or the information service ClaimsFiler.
Comments (0)
No comments yet. Be the first!